Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects



    
    New Peptide shown even more effective compared to hydroquinone




    
    NEW YORK, Aug. 6 /CNW/ -- Lumixyl(TM) a non-toxic, non-irritating,
synthetic peptide technology shown to significantly help improve the
appearance of unwanted discoloration, age spots, sun spots and uneven skin
tone is now available through select physicians to help their patients achieve
picture perfect skin. A hydroquinone alternative, this new cosmeceutical skin
brightening cream can be found in leading physician offices for $120 per 1
ounce pump.

    To view the Multimedia News Release, go to:
http://www.prnewswire.com/mnr/lumixyl/39490/
    

    (Photo:  http://www.newscom.com/cgi-bin/prnh/20090806/NY57783 )

    
    Developed by dermatological researchers at Stanford University, Lumixyl's
ground-breaking technology is the only peptide shown to measurably promote
healthy skin function in restraining tyrosinase, the enzyme responsible for
initiating the overproduction of melanin, that can cause uneven pigmentation
and dark spots.

    Lumixyl is created for patients seeking more even skin-tone including
those with:
    
    --  Melasma
    --  Post-inflammatory hyperpigmentation
    --  Sun spots, age spots or liver spots
    --  Photodamage

    --  Hyperpigmentation caused by systemic disease or prescription drugs

    
    Clinical studies demonstrate that topical use of Lumixyl visibly improves
mild to moderate hyperpigmentation with excellent volunteer satisfaction in as
little as 8 weeks. Studies show that Lumixyl, a chain of ten amino acids,
promoted the moderation of melanin more efficaciously than hydroquinone. At
equal concentrations, skin that was treated with the Lumixyl peptide expressed
a reduced production of melanin by as much as 40 percent compared to those
treated with hydroquinone, which reduced production by only 7 percent in the
study.

    "The results of studies conducted at Stanford are impressive, showing a
40 percent improvement in melanin related darkening.," commented Nowell
Solish, MD, FRCP, Assistant Professor at The University of Toronto,
co-director of the Non-Melanoma Skin Cancer clinic at Women's College. "When
used as directed, Lumixyl appears to significantly help the skin's ability to
diminish dark spots imparting users with brighter, more even skin tone while
limiting irritation, red blotches or even sensitivity to sunlight."

    Moreover, in-use and Repeated Insult Patch Testing (RIPT) studies confirm
that Lumixyl is safe for topical use and does not elicit irritation or
allergic reaction. It does not cause increased sensitivity to sunlight as do
many commonly used brightening agents and is gentle for all skin types and
tones.

    "Hydroquinone has had some controversy in the recent past and this
product offers a non-hydroquinone alternative that shows good clinical
efficacy in treating discoloration without causing irritation," stated Neil
Sadick, MD, FAAD, FAACS, FACP, FACPh.

    Lumixyl Topical Brightening Creme can be used alone or if directed by a
physician, to compliment other treatments such as Tretinoin, laser resurfacing
and SilkPeel(TM), respectively, to diminish dark spots, uneven pigmentation
and improve overall skin tone.
    

    Visible Results without Risk
    
    The RIPT results show that, unlike many alternative lightening
ingredients, this peptide does not cause irritation or allergic reactions.
Lumixyl is formulated to provide the following key advantages:
    
    --  Non-toxic
    --  Non-irritating
    --  Water-soluble
    --  Safe for all skin types
    --  Produces no harmful by-products

    --  Has no cytotoxic effect

    
    Lumixyl products are made exclusively for dermatologists, plastic
surgeons and skin oriented aesthetic physicians. The products are co-marketed
in the United States by Basis Medical Technologies and Envy Medical.

    ABOUT BASIS -- BASIS Medical Technologies specializes in the development
and distribution of groundbreaking technologies in medicine and medical
aesthetics. Headquartered in Toronto, Canada, BASIS is an innovative
technology platform with sales, marketing and training capabilities around the
world. With an experienced management team and medical advisory panel, BASIS
is committed to delivering and developing cutting-edge medical products
internationally. Basis is an exclusive market representative for Lumixyl, a
product licensed by Envy Medical Inc..

    ABOUT ENVY MEDICAL -- Envy Medical, working through its commercial
subsidiary, E Med Inc., develops, markets and sells highly effective
non-invasive skin rejuvenation therapies for patients suffering from either
dermatologic or aesthetic conditions. The Company's lead products include
SilkPeel , a breakthrough device combining exfoliation with dermalinfusion 
for deeper tissue delivery of active ingredients and better patient outcomes.
Envy is also the exclusive licensor of skin brightening peptides including
Lumixyl, developed at Stanford University. The Lumixyl peptide is now also
available as a topical solution for SilkPeel procedures, addressing
hyperpigmentation and photo-damage. More information can be found at
www.4emed.com.

    For more information on Lumixyl or to locate a dispensing physician near
you, please contact: info@basismedtech.com.
    




    




For further information:

For further information: Melissa Kelz, Principal, Melissa Kelz PR,
+1-312-543-8300, melissakelz@kelzpr.com

Organization Profile

BASIS MEDICAL TECHNOLOGIES

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890